Jardiance competitive therapy in HF market despite EMPACT-MI trial outcome, says analyst

US pharm major Eli Lilly (NYSE: LLY) and German partner Boehringer Ingelheim recently presented results of the Phase III EMPACT-MI trial, which examined patients treated with sodium-glucose co-transporter-2 inhibitor (SGLT-2I) Jardiance (empagliflozin) following a heart attack, at the American College of Cardiology’s (ACC).

However, the treatment with empagliflozin did not impact the study’s primary endpoint of a combination of heart failure and hospitalization and all-cause mortality. Despite the outcome of the EMPACT-MI trial, Empagliflozin remains a competitive therapy in the heart failure (HF) market, says pharma analytics company GlobalData.

Data presented from EMPACT-MI investigated the safety and efficacy of empagliflozin in 6,000 patients with acute myocardial infarction (AMI). Empagliflozin has previously been identified to improve cardiovascular (CV) outcomes in patients with HF, patients with type 2 diabetes (T2D) who have high CV risk, and patients with chronic kidney disease (CKD).